1. Home
  2. VOR vs DBVT Comparison

VOR vs DBVT Comparison

Compare VOR & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

HOLD

Current Price

$12.99

Market Cap

562.6M

Sector

Health Care

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$19.51

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOR
DBVT
Founded
2015
2002
Country
United States
France
Employees
N/A
90
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
562.6M
1.1B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
VOR
DBVT
Price
$12.99
$19.51
Analyst Decision
Buy
Buy
Analyst Count
10
7
Target Price
$64.78
$31.75
AVG Volume (30 Days)
565.5K
221.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
2.86
N/A
EPS
N/A
N/A
Revenue
N/A
$4,151,000.00
Revenue This Year
N/A
$65.50
Revenue Next Year
N/A
$47.02
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$3.91
52 Week High
$49.95
$26.19

Technical Indicators

Market Signals
Indicator
VOR
DBVT
Relative Strength Index (RSI) 40.96 41.23
Support Level $11.76 $8.55
Resistance Level $16.88 $24.47
Average True Range (ATR) 1.02 1.50
MACD -0.26 -0.35
Stochastic Oscillator 2.37 16.36

Price Performance

Historical Comparison
VOR
DBVT

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: